Healios K.K.
TSE:4593.T
201 (JPY) • At close November 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Healios K.K. |
Symbool | 4593.T |
Munteenheid | JPY |
Prijs | 199 |
Beurswaarde | 17,936,069,398 |
Dividendpercentage | 0% |
52-weken bereik | 114 - 264 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Tadahisa S. Kagimoto M.D. |
Website | https://www.healios.co.jp |
An error occurred while fetching data.
Over Healios K.K.
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (JPY)
Cijfers zijn in miljoenen (JPY)